实时超声/锥形束CT融合成像引导小肾肿瘤经皮消融:技术报告
本研究评估实时超声/锥形束CT融合成像引导最大径11-17 mm肾肿瘤射频消融的技术成功率和病灶靶向准确性。5例患者共6个病灶,全部实现融合同步、正确靶向和成功消融,1个月和3个月增强CT随访证实原发技术有效率为100%,随访8-26个月无复发。结论认为该融合方法可行,尤其适用于超声难以显示的小肾肿瘤。
要点
- 超声/锥形束CT融合成像可提高超声显示不清的小肾肿瘤(<2 cm)的靶向准确性。
- 融合成像引导下经皮射频消融小肾肿瘤原发技术有效率可达100%,短期随访无复发。
- 术前超声显示困难的小肾肿瘤可考虑采用融合成像辅助定位和监测消融。
核心结论
- 超声/锥形束CT融合成像可安全、可行地引导小肾肿瘤经皮热消融,实现正确靶向和完全消融。
- 对于超声显示不清的小肾细胞癌,融合成像可改善靶向定位并有助于完全消融。
研究设计与样本
- 技术报告类研究,纳入5例患者共6个肾病灶,最大直径11-17 mm,均接受射频消融。
- 术中使用实时超声/锥形束CT融合成像识别并监测肿瘤消融,术前记录人口学、肿瘤特征和平均血清肌酐水平。
- 主要终点为原发技术成功率和正确病灶靶向,术后1个月和3个月以增强CT随访确认原发技术有效性。
关键影像表现/征象
- 所有病例均实现可靠的超声/锥形束CT同步,并据此完成正确靶向和成功经皮消融。
- 融合成像用于识别和监测肿瘤消融过程。
诊断标准与关键数值
- 原发技术成功率和正确病灶靶向为主要终点,所有病例均达到正确靶向和成功消融。
- 术后1个月和3个月增强CT随访确认原发技术有效率为100%。
- 随访8-26个月(平均16个月)未见复发。
临床应用与阅片要点
- 对于超声难以显示的小肾肿瘤,可借助超声/锥形束CT融合成像进行定位和消融监测。
- 融合成像同步可靠时可用于引导经皮射频消融,术后应以增强CT随访评估技术有效性。
局限性
- 样本量小(5例患者、6个病灶),为技术报告类研究。
- 随访时间有限(8-26个月,平均16个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
INTRODUCTION: Fusion imaging is gaining attention as an imaging technique to assist minimally invasive tumour ablation. Ultrasound (US) and computed tomography (CT) are the most common imaging modalities to guide thermal ablation of renal tumours, yet cone-beam CT (CBCT) has recently been described to successfully assist percutaneous renal interventions. Our goal was to evaluate primary technical success and correct lesion targeting of US/CBCT fusion imaging to guide the ablation of kidney masses < 2 cm in a small group of patients.
MATERIAL AND METHODS: Six renal lesions (maximum diameter 11-17 mm) were treated with RFA in 5 different patients using real-time US/CBCT. Fusion imaging was used to identify and monitor tumour ablation. Demographics, tumour characteristics and mean serum creatinine levels were recorded before and after the procedure. Primary technical success and correct lesion targeting represented the main endpoints of the study. Primary technique efficacy was confirmed at 1-month and 3-month contrast-enhanced CT follow-ups.
RESULTS: In all cases, a confident US/CBCT synchronisation was reached and allowed for a correct targeting and a successful percutaneous ablation. Primary technique efficacy was 100%. No recurrence was observed at the follow-up that ranged from 8 to 26 months (mean 16 months).
CONCLUSIONS: US/CBCT fusion proved to be a viable method to precisely guide safe and effective percutaneous thermal ablation in patients with small renal tumours, especially when hardly detectable on US.
KEY POINTS: • US/CBCT fusion imaging for renal ablation is safe and feasible. • US/CBCT fusion imaging allows for an improved targeting and complete ablation of small RCC with poor US-conspicuity.
引用
- Monfardini L, Gennaro N, Orsi F, et al. Real-time US/cone-beam CT fusion imaging for percutaneous ablation of small renal tumours: a technical note. Eur Radiol. 2021. PMID: 33871707. doi:10.1007/s00330-021-07930-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。